2-methyl-N-(4-methylpiperazin-1-yl)propanamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-methyl-N-(4-methylpiperazin-1-yl)propanamide
• 化学式: C₉H₁₉N₃O
• mdl: MFCD03367127
• 分子量: 185.27
• InChiKey: KWCFEZYCFXDHBL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  35.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Thiazolyl-Benzimidazoles
  申请人：Cai Jianping

  公开号：US20100160308A1

  公开（公告）日：2010-06-24

  The invention is directed to compounds of formula (1) and pharmaceutically acceptable salts thereof, methods for the preparation thereof, and methods of use thereof.

  这项发明涉及到式（1）的化合物及其药用可接受盐，其制备方法和使用方法。
• NEW COMPOUNDS
  申请人：Stadtmueller Heinz

  公开号：US20110237598A1

  公开（公告）日：2011-09-29

  The present invention encompasses compounds of general formulae (1 a ) and (1 b ) wherein the groups R 1 to R 5 , A, Q, m, n, p and q are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use as medicaments.

  本发明涵盖通式（1a）和（1b）的化合物，其中R1到R5，A，Q，m，n，p和q的定义如权利要求1所述，适用于治疗因细胞过度或异常增殖而特征化的疾病，并作为药物使用。
• EGFR INHIBITORS AND METHODS OF TREATING DISORDERS
  申请人：Gray Nathanael S.

  公开号：US20120094999A1

  公开（公告）日：2012-04-19

  The present invention relates to novel pyrimidine, pyrrolo-pyrimidine, pyrrolo-pyridine, pyridine, purine and triazine compounds which are able to modulate epidermal growth factor receptor (EGFR), including Her-kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.

  本发明涉及新型嘧啶，吡咯嘧啶，吡咯吡啶，吡啶，嘌呤和三嗪化合物，这些化合物能够调控表皮生长因子受体（EGFR），包括Her-kinases，并且在治疗各种疾病，障碍或条件中使用这些化合物。
• NEW CHEMICAL COMPOUNDS
  申请人：Sapountzis Ioannis

  公开号：US20110130401A1

  公开（公告）日：2011-06-02

  Compounds of general formula (1) wherein A, B, R 1 to R 5 , R x m, n and p are defined as described in the specification, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and the use thereof [as] medicaments.

  通式（1）中，A、B、R1至R5、Rxm、n和p的定义如规范所述，适用于治疗由过度或异常细胞增殖所特征的疾病，含有这种化合物的药物制剂和其用途作为药物。
• PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US20170283422A1

  公开（公告）日：2017-10-05

  The present invention relates to novel pyrimido-diazepinone compounds, methods of modulating protein kinases, including MPS1 (TTK), ERK5 (BMK1, MAPK7), LRKK2, EphA2, polo kinase 1, 2, 3, or 4, Ack1, Ack2, Abl, DCAMKL1, ABL1, Abl mutants, DCAMKL2, ARK5, BRK, MKNK2, FGFR4, TNK1, PLK1, ULK2, PLK4, PRKD1, PRKD2, PRKD3, ROS1, RPS6KA6, TAOK1, TAOK3, TNK2, Bcr-Abl, GAK, cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, Axl, Bmx, BTK, c-kit, CHK2, Flt3, MST2, p70S6K, PDGFR, PKB, PKC, Raf, ROCK-H, Rsk1, SGK, TrkA, TrkB and TrkC, and the use of such compounds in the treatment of various diseases, disorders or conditions.